# Arxada invests CHF 20M to expand niacin production in Visp

Arxada pledged an investment of CHF 20 million (€20.4 million) to expand production at its Visp, Switzerland facility, focusing on niacin, as part of an extended long-term partnership with Royal DSM.

- Type: Investment
- Announced: 2022-09-02
- Where: Visp, Switzerland, Switzerland
- Value: $20.4M (20.0M CHF)
- Status: announced
- Products: niacin, vitamin B3
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Arxada](https://endata.com/companies/53772.md)
- [Royal DSM](https://endata.com/companies/5677.md) (partner)

## Sources

- [nutraingredients.com](https://www.nutraingredients.com/Article/2022/09/02/arxada-and-dsm-target-niacin-growth-as-part-of-an-extended-long-term-partnership/), 2022-09-02: "This significant new investment in our Visp facility secures the site’s long-term future, helping to fuel our future growth."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.